Patenting Antibodies: Why Structure Matters

When a new antibody is discovered, inventors usually focus on its activity. An antibody may bind a particular receptor, block a signaling pathway, neutralize a ligand, inhibit tumor growth, or reduce inflammation. From a scientific perspective, those biological effects may be the most important features of the invention. From a patent perspective, however, a purely functional description can be problematic.

Suppose an inventor discovers an antibody that binds a disease-associated protein and blocks receptor activation. That may be a valuable discovery. But there may be many different antibodies that bind the same protein and produce a similar biological effect. A claim directed broadly to “an antibody that binds target X and blocks activity Y” raises two important questions: Is there prior art that compromises patentability due to claim breadth? Have the inventors fully met the written description and enablement requirements of patentability?

Structure Defines the Antibody

For that reason, antibody patent applications commonly include detailed structural information. This may include:

  • Heavy-chain variable region sequences;

  • Light-chain variable region sequences;

  • Complementarity determining region, or CDR, sequences;

  • Framework region sequences;

  • Amino acid sequence identity ranges;

  • Conserved substitutions;

  • Nucleic acid sequences encoding the antibodies; and

  • Structural variants that retain defined binding or biological properties.

This information helps identify what the inventors actually discovered. It moves the disclosure from a desired result to a defined set of antibody molecules capable of producing that result.

The strongest antibody applications combine structural disclosure with functional characterization. The function explains why the antibody matters. The structure helps define what the invention is.

Why CDRs Matter

The complementarity determining regions are frequently central to antibody patent claims because they participate directly in antigen recognition and binding. Claims may define antibodies by reciting one or more heavy-chain CDRs, one or more light-chain CDRs, or combinations of heavy-chain and light-chain CDRs. Other claims may recite complete variable regions or sequences having specified levels of identity to disclosed variable regions.

This type of claiming can provide meaningful protection while maintaining a structural connection to the antibodies that were actually made and characterized. As a result, CDR-based claims often serve as an important bridge between narrow sequence claims and broader functionally defined claims.

What Have the Courts Said?

Over the last several years, courts have repeatedly expressed skepticism toward broad antibody claims that are defined primarily by the results they achieve. Where many different antibodies may be capable of binding the same target or producing the same biological effect, merely describing the desired function of an antibody may not be sufficient to support broad patent protection.

This does not mean that functional limitations are unimportant. Binding affinity, epitope recognition, neutralization activity, signaling inhibition, and other functional characteristics often remain valuable claim limitations. The broader lesson from the case law is that broad functional claims are generally strongest when they are supported by meaningful structural disclosure.

Functional Data Still Matters

Structural disclosure does not make functional data irrelevant. To the contrary, functional data often strengthens an antibody application. Useful data may include:

  • Binding affinity;

  • Association and dissociation rate constants;

  • Competition data;

  • Epitope mapping;

  • Cross-reactivity data;

  • Blocking or neutralization assays; and

  • Cell-based functional assays.

This data can help distinguish one antibody from another and can support the practical significance of the disclosed molecules. They may also help explain why particular structural features matter.

Balancing the Need for Structural Definition and Functional Breadth

In practice, applicants must strike a balance by combining structural and functional limitations. The goal is to obtain meaningful protection for commercially important variants without disconnecting the claims from the antibodies actually disclosed in the application.

Structural features such as variable-region sequences, CDRs, framework regions, or sequence identity limitations provide a foundation for the claim, while functional characteristics help define the biologically meaningful properties that distinguish the claimed antibodies from others.

A well-prepared antibody application therefore tries to identify specific antibodies in structural detail, describe variants in a way that remains connected to those structures, and provide functional data showing that the disclosed antibodies possess the desired properties.

Practical Takeaway

In antibody patenting, function explains what an antibody does. Structure increasingly defines what can be protected.

Disclaimer: This piece is provided for general informational purposes only and does not constitute legal advice. Patent issues are often complex and highly fact-specific, and no one should act on general information of this kind without consulting qualified patent counsel regarding the particular circumstances involved.